aibio
Debt Financing ·
Nuo Therapeutics receives $325,000 second funding under loan
Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028.
AURX Nuo Therapeutics, Inc.
Nuo Therapeutics (AURX) news
Latest Nuo Therapeutics news
- Debt Financing
Nuo Therapeutics closes $675,000 interim loan at 12% interest
Five lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028.
Nuo Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$2.5 million | -$2.3 million |
| Cash from operations | -$864,971 | -$2.2 million |
| Cash and equivalents | $548,946 | $283,714 |
Questions about Nuo Therapeutics
What is the ticker symbol of Nuo Therapeutics?
Nuo Therapeutics, Inc. trades under the ticker AURX on OTC.
Where is Nuo Therapeutics listed?
Nuo Therapeutics, Inc. is listed on OTC.
Which country or territory is Nuo Therapeutics listed under?
Our directory records Nuo Therapeutics, Inc. under United States.
Does aibio.space cover Nuo Therapeutics?
aibio.space lists Nuo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Nuo Therapeutics profitable?
Nuo Therapeutics, Inc. reported a net loss of $2.5 million for the fiscal year ended Dec 31, 2025, and used $864,971 of cash in operations, per its annual report to the SEC.
How much cash does Nuo Therapeutics have?
$449,325 in cash at Jun 30, 2026, per its 10-Q.
What is the latest Nuo Therapeutics (AURX) stock news?
Our latest story on Nuo Therapeutics, dated Oct 6, 2026: "Nuo Therapeutics receives $325,000 second funding under loan". Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. Source.
Does Nuo Therapeutics have debt, a term loan or convertible notes?
Our latest debt story, dated Oct 6, 2026: "Nuo Therapeutics receives $325,000 second funding under loan". Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. Source.
How can I follow Nuo Therapeutics (AURX) news?
Press Follow on this page to add Nuo Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Nuo Therapeutics so far, in Debt Financing.
Investor discussion: Nuo Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
Listing details
- Company
- Nuo Therapeutics, Inc.
- Ticker
- AURX
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction